Observational studyBMC endocrine disorders2026
Analysis of correlated factors of skin pruritus in type 2 diabetes mellitus.
Observational study in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis investigation employed a prospective observational design to examine pruritus, a common dermatological manifestation in type 2 diabetes mellitus (T2DM) patients that significantly impacts both physical health and psychological status. The primary aim was to elucidate potential risk factors contributing to pruritic symptoms in this patient population.
methodsWe consecutively enrolled T2DM patients presenting to our endocrinology department from April to December 2023. Comprehensive data collection included demographic characteristics, pruritus symptom profiles, and standard biochemical parameters through structured questionnaires. Non-invasive cutaneous assessments measured transepidermal water loss (TEWL) and stratum corneum hydration (SCH). Flow cytometric analysis quantified Th1/Th2 cell populations, while serum concentrations of IL-4 and IFN-γ were determined via ELISA.
resultsAmong 110 participants (26 non-pruritic, 84 pruritic), multivariate analysis identified several significant associations (P < 0.05). Key correlates included fasting plasma glucose (FPG), diabetes duration, presence of diabetic peripheral neuropathy (DPN) or nephropathy, hyperuricemia, IL-4 and IFN-γ levels, and SCH in both upper and lower limbs. Logistic regression showed that FPG, diabetes duration, presence of hyperuricemia, IL-4, and SCH measurements inl ower limbs were the risk factor of pruritus combined T2DM. In chronic pruritus cases, severe symptoms correlated with elevated FPG, increased DPN prevalence, and reduced lower limb SCH compared to milder cases (P < 0.05). Acute pruritus severity showed similar FPG associations, with additional significant SCH reductions in both extremities compared to moderate cases (P < 0.05).
conclusionOur findings suggest that FPG, diabetes duration, presence of hyperuricemia, IL-4, and SCH measurements in lower limbs were the risk factor of pruritus combined T2DM. Chronic pruritus severity appears related to metabolic control, neurological involvement, immune inflammation and skin hydration, while acute cases primarily associate with metabolic, immune inflammation and skin hydration. The observed Th1/Th2 imbalance, with progressive ratio decline accompanying symptom worsening, potentially indicates type 2 inflammatory pathway activation in diabetic patients experiencing pruritus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.